Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Oncotarget
|
June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options
Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
Cancer Cell
|
May 1, 2018
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Xinxin Peng, Xiaoyan Xu, Yumeng Wang, et al.
Nature Communications
|
November 27, 2025
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination
Wenjian Gong, Zhiqi Liao, Fan Xiong, et al.
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
Shen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Oncogene
|
July 25, 2021
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Beike Wang, Wei Zhang, Gao Zhang, et al.
NPJ Precision Oncology
|
March 27, 2021
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
Allen Li, Jamie M Keck, Swapnil Parmar, et al.
NPJ Precision Oncology
|
October 20, 2021
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
Marilyne Labrie, Allen Li, Allison Creason, et al.
Cancer Cell
|
June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang, Daniel J McGrail, Chaoyang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Oncotarget
|
June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options
Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
Cancer Cell
|
May 1, 2018
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Xinxin Peng, Xiaoyan Xu, Yumeng Wang, et al.
Nature Communications
|
November 27, 2025
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination
Wenjian Gong, Zhiqi Liao, Fan Xiong, et al.
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
Shen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Oncogene
|
July 25, 2021
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Beike Wang, Wei Zhang, Gao Zhang, et al.
NPJ Precision Oncology
|
March 27, 2021
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics
Allen Li, Jamie M Keck, Swapnil Parmar, et al.
NPJ Precision Oncology
|
October 20, 2021
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
Marilyne Labrie, Allen Li, Allison Creason, et al.
Cancer Cell
|
June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang, Daniel J McGrail, Chaoyang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Page
of 5